Peptide and Oligonucleotide CDMO Market Size – By Product (Peptide, Oligonucleotides), Service Type (Contract Manufacturing, Contract Development), Application (Therapeutics, Diagnostics, Research), End-use (Pharmaceutical, Biopharmaceutical) – Global For

Peptide and Oligonucleotide CDMO Market Size – By Product (Peptide, Oligonucleotides), Service Type (Contract Manufacturing, Contract Development), Application (Therapeutics, Diagnostics, Research), End-use (Pharmaceutical, Biopharmaceutical) – Global Forecast (2024 – 2032)

The Peptide and Oligonucleotide CDMO Market expand at 12.1% CAGR during 2024-2032, driven by the increasing prevalence of chronic diseases, growing adoption of personalized medicine and targeted therapies, and advancements in biotechnology and pharmaceutical research.

According to WHO, noncommunicable diseases (NCDs) are responsible for 41 million deaths annually, comprising 74% of global mortality. As the global population continues to age and lifestyle factors evolve, the incidence of chronic conditions such as cancer, diabetes, and cardiovascular diseases is on the rise. This demographic trend has led to a growing demand for advanced therapeutics, including peptide-based and oligonucleotide-based drugs, which play crucial roles in targeting specific disease pathways and improving treatment outcomes. Consequently, pharmaceutical and biotechnology companies are ramping up their research and development efforts to address these unmet medical needs, driving the demand for CDMO services.

The Peptide and Oligonucleotide CDMO industry is classified based on product, service type, application, end-use, and region.

Oligonucleotides segment will grow rapidly by 2032, as they play a crucial role in various biological processes and are widely utilized in molecular biology research, diagnostics, and therapeutics. The increasing applications of oligonucleotides in gene editing, RNA interference (RNAi), and nucleic acid-based therapies have boosted their demand. Moreover, advancements in synthetic oligonucleotide manufacturing technologies and the development of novel therapeutic modalities are further driving segment growth.

Contract development will expand rapidly till 2032, as it streamlines their operations, reduces costs, and access specialized expertise and technologies. CDMOs offer a wide range of services, including process development, analytical testing, scale-up, and manufacturing of peptides and oligonucleotides, thereby enabling companies to accelerate their drug development timelines and bring innovative therapies to the market more efficiently.

APAC Peptide and Oligonucleotide CDMO industry will gain traction till 2032, attributed to the presence of a large pool of contract development and manufacturing organizations, favorable government initiatives to promote biotechnology and pharmaceutical research, and the increasing outsourcing activities by multinational pharmaceutical companies to leverage the region's cost-effective manufacturing capabilities. Moreover, the rising prevalence of chronic diseases and the expanding healthcare infrastructure in emerging economies such as China, India, and South Korea are further fueling market growth in the region.